Cosmo First Ltd

- The company currently maintains a healthy financial position with a net debt/equity ratio of 0.3 times and a net debt/EBITDA ratio of 1 time, which they do not see as a concern. - Management did not explicitly mention any upcoming fundraising through debt or equity. - They are undertaking capex of around Rs. 590 Cr (value-add CAPEX on BOPP, BOPET, and CPP lines) and Rs. 100-150 Cr for the Zigly pet care business, but there is no indication of new fundraising to finance this. - The company seems focused on internal cash flows and operational efficiencies to support growth and capex. - They cited ongoing inorganic growth opportunities in pet care (Zigly acquisition), but no specific capital raising plans linked to these were disclosed. - Overall, no current or immediate plans for debt/equity fundraising were mentioned in the transcript.

- The company has done close to Rs. 800 Cr CAPEX, with Rs. 590 Cr remaining for BOPP, CPP lines, and value-add assets on the BOPET line to be completed by March 2025. - Remaining value-add CAPEX for the BOPET line is approximately Rs. 50 Cr. - Planned capacity addition in BOPP and CPP lines is around 80,000 tons with a payback period close to four years. - Zigly (pet care business) is expected to require Rs. 100-150 Cr CAPEX over the next 2-3 years, including operational losses. - Chemical business may not require major CAPEX until 80% utilization is achieved. - The company is pursuing strategic acquisitions in the online pet care space to accelerate growth, with one acquisition deal near finalization. - Focus on sustainability includes sourcing 40-50% power from renewable sources, starting from May 2023, aiding cost rationalization.

- Specialty films sales have grown at a 13% CAGR over the last four years but remained flat in FY23 due to export market inventory corrections. - Volume growth in Q4FY23 compared to Q4FY22 was 7%. - The company expects demand growth of about 10% YoY going forward, especially from FMCG, textile, and consumption-driven industries. - New production lines (2 in FY24, 5 more in FY25) will add capacity; however, a balanced demand-supply situation is anticipated over time. - Specialty plus semi-specialty products are expected to constitute around 60-70% of total sales in about five years. - Zigly pet care division aims for multiple times growth over the next couple of years, planning both organic and inorganic expansion including acquisitions. - The BOPET, CPP, and BOPP line value-add CAPEX of Rs. 500-590 Cr to complete by March 2025 will support sales growth. - A marginal margin uptick was noticed in May 2023, signaling improving business conditions.

- Specialty films portfolio expected to deliver superior returns despite near-term challenges in BOPP and BOPET films. - Working on cost rationalization and R&D projects aimed at adding value in coming quarters and years. - Zigly (pet care business) is growing rapidly, with break-even expected in 3 years; losses to peak in FY24 before improving FY25 onwards. - Cosmo’s specialty chemical subsidiary aims to double revenue in coming years through new product launches. - BOPET and related CAPEX (~Rs. 590 Cr total) focused on value-add assets, enhancing future revenue and margins. - Commodity margins currently low (~1/5th of specialty), but specialty margins remain stable; Q4FY23 seen as bottomed out, with marginal uptick expected. - Volume growth recorded at 7% in Q4FY23 vs Q4FY22. - Renewable power sourcing and cost rationalization initiatives to improve profitability. - CAPEX for new businesses (pet care and chemicals) to aid growth; peak debt manageable (Debt/EBITDA ~1:1).

The transcript does not explicitly mention current or expected orderbook or pending orders details. However, related insights include: - The company continues to work closely with large FMCG players, having signed contracts and developed multiple innovative products for them. - There is ongoing product development and pipeline growth with several large brands. - Specialty films and related segments demonstrate steady demand, with volume growth around 7% YoY mentioned. - Demand is expected to grow about 10% YoY in consumption-driven sectors. - No explicit quantitative orderbook or pending orders numbers were disclosed in the call. Overall, the company signals healthy ongoing order inflow from leading clients and expects growth in specialty product demand but does not provide specific orderbook figures.